-
NMPA Approves Hangzhou Ruidi Biotechnology’s Steep Pulse Therapy Equipment for Tumor Treatment
•
China’s National Medical Products Administration (NMPA) has granted approval to Hangzhou Ruidi Biotechnology Co., Ltd for its steep pulse therapy equipment and disposable steep pulse ablation needle, as reported on the bureau’s website. This marks a significant advancement in the field of minimally invasive interventional treatments for tumors in China.…
-
CDE Expands Care Plan with Approvals for Ractigen’s RAG-17 and Vitalgen’s VGR-R01
•
In a swift succession of actions, China’s Center for Drug Evaluation (CDE) has added two more rare disease drugs to its patient-centered rare disease drug development pilot program, known as the Care Plan. This follows three other approvals within a 10-day period. The latest inclusions are Ractigen Therapeutics’ RAG-17 and…
-
NMPA Drafts Medical Representative Management Measures, Seeks Public Input
•
The National Medical Products Administration (NMPA) has released the “Medical Representative Management Measures (draft proposal)”, which has been developed in consultation with the Ministry of Public Security, National Healthcare Commission, State Administration for Market Regulation, National Healthcare Security Administration, National Administration of Traditional Chinese Medicine, and National Bureau of Disease…
-
Daiichi Sankyo Invests RMB 1.1 Billion in New ADC Manufacturing Plant in Shanghai
•
Japanese pharmaceutical company Daiichi Sankyo (TYO: 4568) is significantly increasing its investment in China with a RMB 1.1 billion outlay to establish a new antibody drug conjugate (ADC) manufacturing plant in Zhangjiang, located in Shanghai’s Pudong New Area. This strategic move by the firm is aimed at addressing the escalating…
-
Jiangsu Kanion Pharmaceutical Gets NMPA Clearance for Oncolytic Virus Product KYS202003A
•
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its investigational product, KYS202003A. The Chinese company is set to initiate a clinical study assessing this Category 1 biologic product for the treatment of advanced solid tumors.…
-
Lingyi Biotechnology and Jolly Pharmaceutical Ink Comprehensive Collaboration Agreement
•
China-based gene therapy specialist Lingyi Biotechnology Co., Ltd has entered into a comprehensive collaboration agreement with Zhejiang Jolly Pharmaceutical Co., Ltd. The partnership aims to leverage the respective strengths of both companies in equity, research and development (R&D), and sales. Enhancing Drug Development and CommercializationUnder the terms of the agreement,…
-
Sichuan Biokin Pharmaceutical’s BL-M08D1 ADC Receives NMPA Approval for Clinical Trials
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) for its antibody drug conjugate (ADC), BL-M08D1, to enter clinical trials. The drug is intended for the treatment of recurrent or refractory hematological malignancies and…
-
Huadong Medicine Receives FDA Clearance for HDM1005 Clinical Study in Obstructive Sleep Apnea
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from the US Food and Drug Administration (FDA) to initiate a clinical study assessing its HDM1005 in patients with obstructive sleep apnea (OSA) who are overweight or obese. HDM1005: A Dual GLP-1 and GIP Receptor AgonistHDM1005…
-
Laekna, Inc. Initiates IND-Enabling Study for Monoclonal Antibody LAE123 in Severe Diseases
•
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced the initiation of an Investigational New Drug (IND)-enabling study for its monoclonal antibody (mAb), LAE123, which has successfully met the preclinical candidate compound (PCC) requirements. This development marks a significant step forward in the drug’s journey towards clinical trials for severe…
-
CORXEL Partners with Apeloa Pharmaceutical for CDMO Services Expansion
•
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced a strategic partnership with CORXEL, formerly known as Ji Xing Pharmaceuticals. The financial details of the agreement have not been disclosed, but it is confirmed that Apeloa will provide professional CDMO services to CORXEL on…
-
Wuhan Union Hospital to Transfer Hereditary Thrombophilia Detection Patent to Kingmed Diagnostics
•
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, also recognized as Wuhan Union Hospital of China, has announced plans to transfer its invention patent, titled “A Primer Probe Combination and Kit for Detecting Common Mutation Sites in Hereditary Thrombophilia Based on ARMS-PCR Method,” to Kingmed Diagnostics (SHA:…
-
Shanghai Yanyin Technology Partners with Castalysis Bioscience to Advance CRISPR Software Development
•
Shanghai Yanyin Technology Co., Ltd has announced a strategic partnership with Castalysis Bioscience (Shanghai), a Shanghai-based gene editing technology developer, to strengthen the research and development and market expansion of CRISPR gene editing module software. The collaboration aims to leverage the technical advantages of both companies to jointly develop a…
-
Eisai and Biogen Launch Alzheimer’s Treatment Leqembi in South Korea
•
Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the commercial launch of their co-developed amyloid-beta (Aβ) monoclonal antibody, Leqembi (lecanemab), in South Korea. The Ministry of Food and Drug Safety (MFDS) had previously approved the drug in May 2024 for the treatment of adult…
-
Bayer AG Launches Bayer Co.Lab Berlin, Focusing on Life Science Innovation
•
Germany-based Bayer AG (ETR: BAYN) has announced the opening of its new life science incubator, Bayer Co.Lab Berlin, which will initially house MyoPax GmbH, a local startup specializing in muscle regeneration therapies through stem cell and gene editing technologies. Expanding Bayer’s Global Incubator NetworkBayer Co.Lab Berlin joins Bayer’s global network…
-
Chinese Pharmacopoeia Commission Approves Draft for ChP 2025 Edition
•
On December 27, the 12th Conference of the Chinese Pharmacopoeia Commission (ChPC) Executive Committee concluded with the approval of the draft for the 2025 edition of the Chinese Pharmacopoeia (ChP 2025 Edition). The approval paves the way for the imminent implementation of the new edition. Enhancements in Scientificity and StandardizationThe…
-
Huadong Medicine’s Arcalyst Receives NMPA Approval for Cryopyrin-Associated Periodic Syndromes
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its drug Arcalyst (rilonacept), indicated for the treatment of cryo-pyrin-associated periodic syndromes (CAPSs), including familial cold autoimmune syndrome (FCAS) and muckle-well syndrome (MWS). Understanding CAPS and Its SubtypesCAPS is a…
-
Huadong Medicine’s Elahere (Mirvetuximab Soravtansine) Approved by NMPA for Ovarian Cancer Treatment
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for Elahere (mirvetuximab soravtansine), an antibody drug conjugate (ADC) targeting folate receptor α (FRα), for the treatment of FRα positive platinum-resistant ovarian cancer (PROC) in patients who have…
-
MicuRx Pharmaceuticals’ MRX-4 Combo Shows Positive Results in Phase III Study
•
Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced positive results from a Phase III study for its drug MRX-4 in combination with contezolid as sequential therapy for complex skin and soft tissue infections. The study successfully met its primary efficacy endpoint, demonstrating good clinical and microbiological efficacy. The regimen’s…
-
National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs
•
The National Medical Products Administration has released the finalized National Reimbursement Drug List (NRDL) for 2024, which includes 91 new drugs. Among these, 89 were added through negotiation/pricing bidding, and 2 were winning bids in the volume-based procurement (VBP). Concurrently, 43 drugs that had been supplanted in clinical use or…
-
Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs
•
Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs), has reportedly raised $42 million via a Series A financing round. The funding round was led by Lanchi Ventures, with additional contributions from YuanBio Venture Capital, Legend Capital, and Xiamen…
